Year |
Citation |
Score |
2023 |
Clemens PR, Gordish-Dressman H, Niizawa G, Gorni K, Guglieri M, Connolly AM, Wicklund M, Bertorini T, Mah J, Thangarajh M, Smith EC, Kuntz NL, McDonald CM, Henricson E, Upadhyayula S, et al. Findings from the Longitudinal CINRG Becker Natural History Study. Journal of Neuromuscular Diseases. PMID 37980682 DOI: 10.3233/JND-230178 |
0.309 |
|
2023 |
Reay DP, Tabib T, Wang Y, Oriss TB, Young NA, Lafyatis RA, Jarjour WN, Clemens PR, Ascherman DP. Antigen-driven T cell-macrophage interactions mediate the interface between innate and adaptive immunity in histidyl-tRNA synthetase-induced myositis. Frontiers in Immunology. 14: 1238221. PMID 37809058 DOI: 10.3389/fimmu.2023.1238221 |
0.311 |
|
2023 |
Madrid DA, Knapp RA, Lynch D, Clemens P, Weaver AA, Puwanant A. Associations between Lower Extremity Muscle Fat Fraction and Motor Performance in Myotonic Dystrophy Type 2: A Pilot Study. Muscle & Nerve. PMID 36938823 DOI: 10.1002/mus.27821 |
0.304 |
|
2020 |
Dang UJ, Ziemba M, Clemens PR, Hathout Y, Conklin LS, Hoffman EP. Serum biomarkers associated with baseline clinical severity in young steroid-naive Duchenne muscular dystrophy boys. Human Molecular Genetics. PMID 32592467 DOI: 10.1093/Hmg/Ddaa132 |
0.462 |
|
2020 |
Clemens PR, Niizawa G, Feng J, Florence J, D'Alessandro AS, Morgenroth LP, Gorni K, Guglieri M, Connolly A, Wicklund M, Bertorini T, Mah JK, Thangarajh M, Smith E, Kuntz N, et al. The CINRG Becker Natural History Study: Baseline Characteristics. Muscle & Nerve. PMID 32564389 DOI: 10.1002/Mus.27011 |
0.354 |
|
2020 |
Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, McDonald CM, Zaidman CM, Morgenroth LP, Osaki H, Satou Y, Yamashita T, Hoffman EP. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. Jama Neurology. PMID 32453377 DOI: 10.1001/Jamaneurol.2020.1264 |
0.305 |
|
2019 |
Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, McDonald CM, Kuntz NL, Finkel RS, Guglieri M, Bushby K, Tulinius M, Nevo Y, Ryan MM, Webster R, ... ... Clemens PR, et al. Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function. Neurology. PMID 31451516 DOI: 10.1212/Wnl.0000000000008168 |
0.415 |
|
2019 |
Hathout Y, Liang C, Ogundele M, Xu G, Tawalbeh SM, Dang UJ, Hoffman EP, Gordish-Dressman H, Conklin LS, van den Anker JN, Clemens PR, Mah JK, Henricson E, McDonald C. Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy. Scientific Reports. 9: 12167. PMID 31434957 DOI: 10.1038/S41598-019-48548-9 |
0.314 |
|
2019 |
Kishnani P, Schoser B, Bratkovic D, Byrne BJ, Clemens PR, Goker-Alpan O, Ming X, Roberts M, Schwenkreis P, Sivakumar K, van der Ploeg AT, Jain V, Sitaraman S, Barth JA, Lagast H, et al. First-in-human study of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in patients with Pompe disease: preliminary functional assessment results from the ATB200-02 trial Molecular Genetics and Metabolism. 126: S86. DOI: 10.1016/J.Ymgme.2018.12.212 |
0.315 |
|
2019 |
Clemens P, Mengle-Gaw L, Smith E, Castro D, Mah J, McDonald C, Kuntz N, Finkel R, Guglieri M, Tulinius M, Nevo Y, Ryan M, Webster R, Morgenroth L, Siener C, et al. P.338Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function Neuromuscular Disorders. 29. DOI: 10.1016/J.Nmd.2019.06.452 |
0.429 |
|
2018 |
Thangarajh M, Spurney CF, Gordish-Dressman H, Clemens PR, Hoffman EP, McDonald CM, Henricson EK, Investigators C. Neurodevelopmental Needs in Young Boys with Duchenne Muscular Dystrophy (DMD): Observations from the Cooperative International Neuromuscular Research Group (CINRG) DMD Natural History Study (DNHS). Plos Currents. 10. PMID 30443431 DOI: 10.1371/Currents.Md.4Cdeb6970E54034Db2Bc3Dfa54B4D987 |
0.33 |
|
2015 |
Reay DP, Bastacky SI, Wack KE, Stolz DB, Robbins PD, Clemens PR. D-Amino Acid Substitution of Peptide-Mediated NF-κB Suppression in mdx Mice Preserves Therapeutic Benefit in Skeletal Muscle, but Causes Kidney Toxicity. Molecular Medicine (Cambridge, Mass.). 21: 442-52. PMID 26018805 DOI: 10.2119/Molmed.2013.00141 |
0.349 |
|
2015 |
Clemens P, Reay D, Bastacky S, Wack K, Stolz D, Robbins P. D-amino acid substitution of peptide-mediated NF-κB suppression in mdx mice preserves therapeutic benefit in skeletal muscle, but causes kidney toxicity Neuromuscular Disorders. 25. DOI: 10.1016/J.Nmd.2015.06.388 |
0.413 |
|
2014 |
Cai L, Koppanati BM, Bertoni C, Clemens PR. In utero delivery of oligodeoxynucleotides for gene correction. Methods in Molecular Biology (Clifton, N.J.). 1114: 399-411. PMID 24557918 DOI: 10.1007/978-1-62703-761-7_26 |
0.812 |
|
2014 |
Spurney C, Shimizu R, Morgenroth LP, Kolski H, Gordish-Dressman H, Clemens PR. Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle & Nerve. 50: 250-6. PMID 24395289 DOI: 10.1002/Mus.24163 |
0.303 |
|
2014 |
Mah J, Chen Y, Duong T, Cnaan A, Sund Z, Morgenroth L, McDonald C, Tulinius M, Sparks S, Webster R, Connolly A, Karachunski P, Clemens P. G.P.13 Neuromuscular Disorders. 24: 798. DOI: 10.1016/J.Nmd.2014.06.027 |
0.347 |
|
2013 |
Henricson EK, Abresch RT, Cnaan A, Hu F, Duong T, Arrieta A, Han J, Escolar DM, Florence JM, Clemens PR, Hoffman EP, McDonald CM. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle & Nerve. 48: 55-67. PMID 23649481 DOI: 10.1002/Mus.23808 |
0.396 |
|
2013 |
Fernandez I, Harlow L, Zang Y, Liu-Bryan R, Ridgway W, Clemens P, Ascherman D. P.14.9 Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-tRNA synthetase-induced myositis Neuromuscular Disorders. 23: 815-816. DOI: 10.1016/J.Nmd.2013.06.617 |
0.395 |
|
2012 |
Charan RA, Niizawa G, Nakai H, Clemens PR. Adeno-associated virus serotype 8 (AAV8) delivery of recombinant A20 to skeletal muscle reduces pathological activation of nuclear factor (NF)-κB in muscle of mdx mice. Molecular Medicine (Cambridge, Mass.). 18: 1527-35. PMID 23154638 DOI: 10.2119/Molmed.2012.00299 |
0.515 |
|
2012 |
Abdel-Hamid H, Clemens PR. Pharmacological therapies for muscular dystrophies. Current Opinion in Neurology. 25: 604-8. PMID 22941265 DOI: 10.1097/Wco.0B013E328357F44C |
0.316 |
|
2012 |
Eghtesad S, Jhunjhunwala S, Little SR, Clemens PR. Effect of rapamycin on immunity induced by vector-mediated dystrophin expression in mdx skeletal muscle. Scientific Reports. 2: 399. PMID 22570764 DOI: 10.1038/Srep00399 |
0.842 |
|
2012 |
Escolar DM, Zimmerman A, Bertorini T, Clemens PR, Connolly AM, Mesa L, Gorni K, Kornberg A, Kolski H, Kuntz N, Nevo Y, Tesi-Rocha C, Nagaraju K, Rayavarapu S, Hache LP, et al. Pentoxifylline as a rescue treatment for DMD: a randomized double-blind clinical trial. Neurology. 78: 904-13. PMID 22402864 DOI: 10.1212/Wnl.0B013E31824C46Be |
0.441 |
|
2012 |
Reay DP, Niizawa GA, Watchko JF, Daood M, Reay JC, Raggi E, Clemens PR. Effect of nuclear factor κB inhibition on serotype 9 adeno-associated viral (AAV9) minidystrophin gene transfer to the mdx mouse. Molecular Medicine (Cambridge, Mass.). 18: 466-76. PMID 22231732 DOI: 10.2119/Molmed.2011.00404 |
0.584 |
|
2012 |
Charan RA, Hanson R, Clemens PR. Deubiquitinating enzyme A20 negatively regulates NF-κB signaling in skeletal muscle in mdx mice. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 587-95. PMID 22012122 DOI: 10.1096/Fj.11-189829 |
0.484 |
|
2011 |
Reay DP, Yang M, Watchko JF, Daood M, O'Day TL, Rehman KK, Guttridge DC, Robbins PD, Clemens PR. Systemic delivery of NEMO binding domain/IKKγ inhibitory peptide to young mdx mice improves dystrophic skeletal muscle histopathology. Neurobiology of Disease. 43: 598-608. PMID 21624467 DOI: 10.1016/J.Nbd.2011.05.008 |
0.481 |
|
2011 |
Eghtesad S, Jhunjhunwala S, Little SR, Clemens PR. Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle. Molecular Medicine (Cambridge, Mass.). 17: 917-24. PMID 21607286 DOI: 10.2119/Molmed.2010.00256 |
0.828 |
|
2011 |
Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X, Tremblay JP. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 830-40. PMID 21468001 DOI: 10.1038/Mt.2011.59 |
0.539 |
|
2011 |
Soejima M, Kang EH, Gu X, Katsumata Y, Clemens PR, Ascherman DP. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. Arthritis and Rheumatism. 63: 479-87. PMID 21280002 DOI: 10.1002/Art.30113 |
0.301 |
|
2011 |
Peterson JM, Kline W, Canan BD, Ricca DJ, Kaspar B, Delfín DA, DiRienzo K, Clemens PR, Robbins PD, Baldwin AS, Flood P, Kaumaya P, Freitas M, Kornegay JN, Mendell JR, et al. Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Molecular Medicine (Cambridge, Mass.). 17: 508-15. PMID 21267511 DOI: 10.2119/Molmed.2010.00263 |
0.358 |
|
2011 |
Homayoun H, Khavandgar S, Hoover JM, Mohsen AW, Vockley J, Lacomis D, Clemens PR. Novel mutation in MYH7 gene associated with distal myopathy and cardiomyopathy. Neuromuscular Disorders : Nmd. 21: 219-22. PMID 21211974 DOI: 10.1016/J.Nmd.2010.12.005 |
0.436 |
|
2011 |
Wang L, Eghtesad S, Clemens PR. Migration of dendritic cells from murine skeletal muscle. Immunobiology. 216: 195-9. PMID 20580121 DOI: 10.1016/J.Imbio.2010.04.006 |
0.812 |
|
2010 |
Eghtesad S, Zheng H, Nakai H, Epperly MW, Clemens PR. Effects of irradiating adult mdx mice before full-length dystrophin cDNA transfer on host anti-dystrophin immunity. Gene Therapy. 17: 1181-90. PMID 20827278 DOI: 10.1038/Gt.2010.108 |
0.828 |
|
2010 |
Tang Y, Reay DP, Salay MN, Mi MY, Clemens PR, Guttridge DC, Robbins PD, Huard J, Wang B. Inhibition of the IKK/NF-κB pathway by AAV gene transfer improves muscle regeneration in older mdx mice. Gene Therapy. 17: 1476-83. PMID 20720575 DOI: 10.1038/Gt.2010.110 |
0.549 |
|
2010 |
Koppanati BM, Li J, Reay DP, Wang B, Daood M, Zheng H, Xiao X, Watchko JF, Clemens PR. Improvement of the mdx mouse dystrophic phenotype by systemic in utero AAV8 delivery of a minidystrophin gene. Gene Therapy. 17: 1355-62. PMID 20535217 DOI: 10.1038/Gt.2010.84 |
0.838 |
|
2010 |
van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. The New England Journal of Medicine. 362: 1396-406. PMID 20393176 DOI: 10.1056/Nejmoa0909859 |
0.331 |
|
2009 |
Clemens PR, Eghtesad S, Reay DP. Gene therapy for muscular dystrophy reaches human clinical trial. Annals of Neurology. 66: 267-70. PMID 19798643 DOI: 10.1002/Ana.21803 |
0.775 |
|
2009 |
Koppanati BM, Li J, Xiao X, Clemens PR. Systemic delivery of AAV8 in utero results in gene expression in diaphragm and limb muscle: treatment implications for muscle disorders. Gene Therapy. 16: 1130-7. PMID 19474806 DOI: 10.1038/Gt.2009.71 |
0.839 |
|
2009 |
Eghtesad S, Morel PA, Clemens PR. The companions: regulatory T cells and gene therapy. Immunology. 127: 1-7. PMID 19368560 DOI: 10.1111/J.1365-2567.2009.03069.X |
0.787 |
|
2008 |
Reay DP, Bilbao R, Koppanati BM, Cai L, O'Day TL, Jiang Z, Zheng H, Watchko JF, Clemens PR. Full-length dystrophin gene transfer to the mdx mouse in utero. Gene Therapy. 15: 531-6. PMID 18273052 DOI: 10.1038/Gt.2008.8 |
0.842 |
|
2007 |
Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, Fertig N, Oury T, Vandersteen D, Clemens P, Camacho CJ, Weinberg A, Ascherman DP. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation Journal of Autoimmunity. 29: 174-186. PMID 17826948 DOI: 10.1016/J.Jaut.2007.07.005 |
0.415 |
|
2006 |
Jiang Z, Clemens PR. Cellular caspase-8-like inhibitory protein (cFLIP) prevents inhibition of muscle cell differentiation induced by cancer cells. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 2570-2. PMID 17060399 DOI: 10.1096/Fj.06-6347Fje |
0.416 |
|
2006 |
Maamary JR, Jiang Z, Clemens PR. 574. Models of Cancer Cachexia: Treatment with Inhibition of NF-kB Molecular Therapy. 13: S221. DOI: 10.1016/J.Ymthe.2006.08.647 |
0.407 |
|
2006 |
Koppanati BM, Li J, Wang B, Xiao X, Clemens PR. 567. Adeno-Associated Virus Vector 8 (AAV8) Provides Efficient Gene Delivery to Skeletal Muscles In Utero by Systemic Adminstration Molecular Therapy. 13: S218. DOI: 10.1016/J.Ymthe.2006.08.640 |
0.838 |
|
2006 |
Reay DP, Sae-chew P, Clemens PR. 915. High and Low Affinity Consensus Binding Sequences to Extracellular α7 Integrin X2B Subunit Detected Using Phage Display Biopanning Molecular Therapy. 13: S352-S353. DOI: 10.1016/J.Ymthe.2006.08.1005 |
0.317 |
|
2005 |
Escolar DM, Buyse G, Henricson E, Leshner R, Florence J, Mayhew J, Tesi-Rocha C, Gorni K, Pasquali L, Patel KM, McCarter R, Huang J, Mayhew T, Bertorini T, Carlo J, ... ... Clemens PR, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Annals of Neurology. 58: 151-5. PMID 15984021 DOI: 10.1002/Ana.20523 |
0.472 |
|
2005 |
Bilbao R, Reay DP, Li J, Xiao X, Clemens PR. Patterns of gene expression from in utero delivery of adenoviral-associated vector serotype 1. Human Gene Therapy. 16: 678-84. PMID 15960599 DOI: 10.1089/Hum.2005.16.678 |
0.547 |
|
2005 |
Bilbao R, Reay DP, Wu E, Zheng H, Biermann V, Kochanek S, Clemens PR. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero. Gene Therapy. 12: 39-47. PMID 15483668 DOI: 10.1038/Sj.Gt.3302392 |
0.561 |
|
2005 |
Bilbao R, Reay DP, Li J, Xiao X, Clemens PR. 1086. Patterns of Gene Expression from In Utero Delivery of AAV Serotype 1 Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.633 |
0.547 |
|
2004 |
Jiang Z, Schiedner G, van Rooijen N, Liu CC, Kochanek S, Clemens PR. Sustained muscle expression of dystrophin from a high-capacity adenoviral vector with systemic gene transfer of T cell costimulatory blockade. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 688-96. PMID 15451453 DOI: 10.1016/J.Ymthe.2004.07.020 |
0.567 |
|
2004 |
Jiang Z, Schiedner G, Gilchrist SC, Kochanek S, Clemens PR. CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle. Gene Therapy. 11: 1453-61. PMID 15269713 DOI: 10.1038/Sj.Gt.3302315 |
0.798 |
|
2004 |
Bilbao R, Reay DP, Koppanati BM, Clemens PR. Biocompatibility of adenoviral vectors in poly(vinyl chloride) tubing catheters with presence or absence of plasticizer di-2-ethylhexyl phthalate. Journal of Biomedical Materials Research. Part A. 69: 91-6. PMID 14999755 DOI: 10.1002/Jbm.A.20116 |
0.767 |
|
2004 |
Reay DP, Bilbao R, Wu E, O'Day TL, Watchko JF, Clemens PR. 382. In Utero Intramuscular Delivery of a High-Capacity Adenoviral Vector Carrying a Full-Length Murine Dystrophin cDNA Provides Functional Benefit and Reassembly of the Dystrophin-Glycoprotein Complex in Hind Limb Muscles of mdx Mice Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.321 |
0.602 |
|
2004 |
Jiang Z, Clemens PR. 248. cFLIP or IKBSR Inhibition of NF-|[kappa]|B Activation in Mouse Myoblast Cells: Potential Application of Gene Therapy for Cancer Cachexia Molecular Therapy. 9. DOI: 10.1016/J.Ymthe.2004.06.189 |
0.438 |
|
2003 |
Bilbao R, Reay DP, Hughes T, Biermann V, Volpers C, Goldberg L, Bergelson J, Kochanek S, Clemens PR. Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors. Gene Therapy. 10: 1821-9. PMID 12960972 DOI: 10.1038/Sj.Gt.3302084 |
0.758 |
|
2003 |
Burwinkel B, Hu B, Schroers A, Clemens PR, Moses SW, Shin YS, Pongratz D, Vorgerd M, Kilimann MW. Muscle glycogenosis with low phosphorylase kinase activity: mutations in PHKA1, PHKG1 or six other candidate genes explain only a minority of cases. European Journal of Human Genetics : Ejhg. 11: 516-26. PMID 12825073 DOI: 10.1038/sj.ejhg.5200996 |
0.354 |
|
2003 |
Bilbao R, Srinivasan S, Reay D, Goldberg L, Hughes T, Roelvink PW, Einfeld DA, Wickham TJ, Clemens PR. Binding of adenoviral fiber knob to the coxsackievirus-adenovirus receptor is crucial for transduction of fetal muscle. Human Gene Therapy. 14: 645-9. PMID 12804146 DOI: 10.1089/104303403321618155 |
0.74 |
|
2002 |
Jiang Z, Feingold E, Kochanek S, Clemens PR. Systemic delivery of a high-capacity adenoviral vector expressing mouse CTLA4Ig improves skeletal muscle gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 369-76. PMID 12231173 DOI: 10.1006/Mthe.2002.0676 |
0.512 |
|
2002 |
Gilchrist SC, Ontell MP, Kochanek S, Clemens PR. Immune response to full-length dystrophin delivered to Dmd muscle by a high-capacity adenoviral vector. Molecular Therapy : the Journal of the American Society of Gene Therapy. 6: 359-68. PMID 12231172 DOI: 10.1006/Mthe.2002.0675 |
0.777 |
|
2002 |
Clemens PR, Duncan FJ. Progress in gene therapy for Duchenne muscular dystrophy. Current Neurology and Neuroscience Reports. 1: 89-96. PMID 11898504 DOI: 10.1007/S11910-001-0080-0 |
0.453 |
|
2002 |
Zivkovic SA, Lacomis D, Clemens PR. Chronic eosinophilic perimyositis with persistent myalgias. Muscle & Nerve. 25: 461-5. PMID 11870728 DOI: 10.1002/Mus.10054 |
0.438 |
|
2001 |
Liu F, Nishikawa M, Clemens PR, Huang L. Transfer of full-length Dmd to the diaphragm muscle of Dmd(mdx/mdx) mice through systemic administration of plasmid DNA. Molecular Therapy : the Journal of the American Society of Gene Therapy. 4: 45-51. PMID 11472105 DOI: 10.1006/Mthe.2001.0419 |
0.569 |
|
2001 |
Jiang ZL, Reay D, Kreppel F, Gambotto A, Feingold E, Kochanek S, McCarthy SA, Clemens PR. Local high-capacity adenovirus-mediated mCTLA4Ig and mCD40Ig expression prolongs recombinant gene expression in skeletal muscle. Molecular Therapy : the Journal of the American Society of Gene Therapy. 3: 892-900. PMID 11407903 DOI: 10.1006/Mthe.2001.0331 |
0.603 |
|
2001 |
Escolar DM, Henricson EK, Mayhew J, Florence J, Leshner R, Patel KM, Clemens PR. Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children. Muscle & Nerve. 24: 787-93. PMID 11360262 DOI: 10.1002/Mus.1070 |
0.404 |
|
1999 |
Bouri K, Feero WG, Myerburg MM, Wickham TJ, Kovesdi I, Hoffman EP, Clemens PR. Polylysine modification of adenoviral fiber protein enhances muscle cell transduction. Human Gene Therapy. 10: 1633-40. PMID 10428208 DOI: 10.1089/10430349950017635 |
0.558 |
|
1999 |
Chen HH, Mack LM, Choi SY, Ontell M, Kochanek S, Clemens PR. DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. Human Gene Therapy. 10: 365-73. PMID 10048389 DOI: 10.1089/10430349950018814 |
0.527 |
|
1998 |
Floyd SS, Clemens PR, Ontell MR, Kochanek S, Day CS, Yang J, Hauschka SD, Balkir L, Morgan J, Moreland MS, Feero GW, Epperly M, Huard J. Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Therapy. 5: 19-30. PMID 9536261 DOI: 10.1038/Sj.Gt.3300549 |
0.625 |
|
1997 |
Feero WG, Rosenblatt JD, Huard J, Watkins SC, Epperly M, Clemens PR, Kochanek S, Glorioso JC, Partridge TA, Hoffman EP. Viral gene delivery to skeletal muscle: insights on maturation-dependent loss of fiber infectivity for adenovirus and herpes simplex type 1 viral vectors. Human Gene Therapy. 8: 371-80. PMID 9054512 DOI: 10.1089/Hum.1997.8.4-371 |
0.425 |
|
1997 |
Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, Clemens PR. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proceedings of the National Academy of Sciences of the United States of America. 94: 1645-50. PMID 9050832 DOI: 10.1073/Pnas.94.5.1645 |
0.562 |
|
1997 |
Hoffman EP, Clemens PR. HyperCKemic, proximal muscular dystrophies and the dystrophin membrane cytoskeleton, including dystrophinopathies, sarcoglycanopathies, and merosinopathies. Current Opinion in Rheumatology. 8: 528-38. PMID 9018456 DOI: 10.1097/00002281-199611000-00006 |
0.361 |
|
1996 |
Kochanek S, Clemens PR, Mitani K, Chen HH, Chan S, Caskey CT. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proceedings of the National Academy of Sciences of the United States of America. 93: 5731-6. PMID 8650161 DOI: 10.1073/Pnas.93.12.5731 |
0.506 |
|
1996 |
North KN, Miller G, Iannaccone ST, Clemens PR, Chad DA, Bella I, Smith TW, Beggs AH, Specht LA. Cognitive dysfunction as the major presenting feature of Becker's muscular dystrophy. Neurology. 46: 461-5. PMID 8614513 DOI: 10.1212/Wnl.46.2.461 |
0.395 |
|
1996 |
Clemens PR, Kochanek S, Chan S, Graham FL, Thomas Caskey C. Adenoviral gene therapy for duchenne muscular dystrophy Neuromuscular Disorders. 6: S24. DOI: 10.1016/0960-8966(96)89025-0 |
0.425 |
|
1995 |
Clemens PR, Krause TL, Chan S, Korb KE, Graham FL, Caskey CT. Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery. Human Gene Therapy. 6: 1477-85. PMID 8573620 DOI: 10.1089/Hum.1995.6.11-1477 |
0.547 |
|
1995 |
Wehner M, Clemens PR, Engel AG, Kilimann MW. Human muscle glycogenosis due to phosphorylase kinase deficiency associated with a nonsense mutation in the muscle isoform of the alpha subunit. Human Molecular Genetics. 3: 1983-7. PMID 7874115 DOI: 10.1093/HMG/3.11.1983 |
0.358 |
|
1993 |
Morsy MA, Mitani K, Clemens P, Caskey CT. Progress toward human gene therapy. Jama. 270: 2338-45. PMID 8230597 DOI: 10.1001/Jama.1993.03510190094033 |
0.402 |
|
1993 |
Mitani K, Clemens PR, Moseley AB, Caskey CT. Gene transfer therapy for heritable disease: cell and expression targeting. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 339: 217-24. PMID 8097051 DOI: 10.1098/rstb.1993.0019 |
0.341 |
|
1992 |
Clemens PR, Ward PA, Caskey CT, Bulman DE, Fenwick RG. Premature chain termination mutation causing Duchenne muscular dystrophy. Neurology. 42: 1775-82. PMID 1513469 DOI: 10.1212/Wnl.42.9.1775 |
0.377 |
|
Show low-probability matches. |